Table 2. Current recommendations for non-conventional therapies for Peyronie’s disease.
| Treatment | Canadian Urological Association (CUA, 2018) | American Urological Association (AUA, 2015) | European Association of Urology (EAU, 2017) |
|---|---|---|---|
| Platelet-rich plasma (PRP) | No Level 1–4 or Grade A-C Evidence for treatment of PD. All current commercial and FDA therapies are not recommended as treatments for PD | Not available | Not available |
| Hyaluronic acid (HA) | Not recommended to use HA therapies for the treatment of PD | Not available | Not available |
| Extracorporeal shockwave therapy (ESWT) | Level 2 evidence, Grade C recommendation. Does not support the use of ESWT for reduction of penile curvature or plaque size | Not recommended to use ESWT for reduction of penile curvature or plaque size in PD (moderate recommendation; evidence strength Grade B). Clinicians may offer ESWT to improve penile pain (conditional recommendation; evidence strength Grade B) | ESWT fails to improve penile curvature and plaque size but may be beneficial for penile pain in PD (Level 1C evidence, Grade B recommendation) |
| Combination hyaluronic acid and platelet rich plasma | Not available | Not available | Not available |
| Stem cell therapy (SCT) | Not recommended as a treatment for PD | Not available | Not available |
| Mycophenolate mofetil (MMF) | Not available | Not available | Not available |
| H-100 | Not available | Not available | Not available |